The 30-day mortality rates among patients undergoing transcatheter aortic valve replacement (TAVR) have decreased by more than half over the last decade, with significant differences between genders, a CENTER* collaboration analysis has shown.
The antithrombotic potency of ticagrelor alone on ex vivo whole blood thrombogenicity does not differ from that of ticagrelor plus aspirin in high-risk patients who have undergone percutaneous coronary intervention (PCI), according to the thrombogenicity substudy of the TWILIGHT* trial.
In patients with high-bleeding risk, undergoing PCI* with a polymer-based drug-eluting stent (DES) was noninferior to a polymer-free drug-coated stent (DCS) when followed by a 1-month dual antiplatelet therapy (DAPT), according to the Onyx ONE** trial presented at TCT 2019.
In low-risk patients with severe aortic stenosis (AS), those treated with transcatheter aortic valve replacement (TAVR) had a significantly better disease-specific health status at 1 year compared with those who received surgical aortic valve replacement (SAVR), according to the PARTNER 3* trial presented at TCT 2019.
Subgroup analyses of the GLOBAL LEADERS study showed similar treatment effects between ticagrelor and aspirin monotherapy following percutaneous coronary intervention (PCI) in patients with impaired renal function (IRF)* and diabetes.
Shorter courses of dual antiplatelet therapy do not perform worse than longer regimens, according to a recent study presented at the 31st Transcatheter Cardiovascular Therapeutics scientific symposium (TCT 2019).
Patients with severe aortic stenosis and intermediate surgical risk may benefit from either transcatheter (TAVR) or surgical aortic valve replacement (SAVR) through 5 years of follow-up, according to midterm data from the PARTNER 2A trial presented at the 31st Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium.
The efficacy of transcatheter mitral-valve repair with the MitraClip device plus guideline-directed medical therapy (GDMT) over GDMT only in reducing hospitalizations for heart failure (HHF) among patients with HF and secondary mitral regurgitation (MR) was sustained at 3 years, including in patients who crossed over from GDMT alone at 2 years, updated results of the COAPT* trial show.
The efficacy and safety of the two-bag (TB) system are comparable to those of the one-bag (OB) system in adults with diabetic ketoacidosis (DKA), results of a study have shown. Both approaches can be considered in adult DKA patients.
Dr. Hsu Li Yang, Dr. Tan Thuan Tong, Dr. Andrea Kwa,
08 Jan 2021
Antimicrobial resistance has become increasingly dire as the rapid emergence of drug resistance, especially gram-negative pathogens, has outpaced the development of new antibiotics. At a recent virtual symposium, Dr Hsu Li Yang, Vice Dean (Global Health) and Programme Leader (Infectious Diseases), NUS Saw Swee Hock School of Public Health, presented epidemiological data on multidrug-resistant (MDR) gram-negative bacteria (GNB) in Asia, while Dr Tan Thuan Tong, Head and Senior Consultant, Department of Infectious Diseases, Singapore General Hospital (SGH), focused on the role of ceftazidime-avibactam in MDR GNB infections. Dr Andrea Kwa, Assistant Director of Research, Department of Pharmacy, SGH, joined the panel in an interactive fireside chat, to discuss challenges, practical considerations, and solutions in MDR gram-negative infections. This Pfizer-sponsored symposium was chaired by Dr Ng Shin Yi, Head and Senior Consultant of Surgical Intensive Care, SGH.